Healthcare >> CEO Interviews >> October 14, 2002
STEPHEN SUDOVAR, President and CEO of Elusys Therapeutics, Inc., is a
highly respected industry veteran with extensive experience in both
large pharmaceutical companies and entrepreneurial business management.
Before taking the helm at Elusys, Mr. Sudovar was President of Roche
Laboratories, Inc., a US division of Hoffmann-La Roche, one of the top
five global pharmaceutical companies. In his 10 years at Roche, Mr.
Sudovar presided over a three-fold increase in the company's US
revenues, a substantial increase in its share of the US market, and the
integration of two pharmaceutical company acquisitions. Prior to working
at Roche, Mr. Sudovar founded Pracon, Inc., a healthcare consulting and
communications firm. As President and CEO he was responsible for the
profitable and rapid growth of the company. Pracon virtually doubled in
size for each of the first seven years. Earlier in his career Mr.
Sudovar was selected to participate in the President's Executive
Interchange Program. In this program he worked as Deputy Administrator
for planning evaluation and legislation for the Environmental Protection
Agency, for which he received a special recognition award from the
President of the United States. Mr. Sudovar has been Chairman of the
Board of Directors of the National Pharmaceutical Council, Chairman of
the Marketing Section at PhRMA, Chairman of the Board of Pracon, Inc.
and a board member of Hoffmann-La Roche, Inc. Mr. Sudovar received his
BS from St. Peter's College and his MBA from Fairleigh Dickinson
University. Profile
Mr. Sudovar: Elusys is a biopharmaceutical company focused on the
development and commercialization of monoclonal antibody
